Pharmigene, Inc. (TPEX:7595)
Taiwan · Delayed Price · Currency is TWD 8.60
+0.60 (7.50%)
Jun 3, 2026, 1:16 PM CST
Pharmigene Revenue
In the year 2025, Pharmigene had annual revenue of 199.89M TWD with 71.53% growth. Pharmigene had revenue of 119.22M in the half year ending December 31, 2025, with 50.67% growth.
Revenue
199.89M
Revenue Growth
+71.53%
P/S Ratio
2.25
Revenue / Employee
n/a
Employees
n/a
Market Cap
449.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 199.89M | 83.36M | 71.53% |
| Dec 31, 2024 | 116.53M | -16.17M | -12.19% |
| Dec 31, 2023 | 132.71M | -1.09M | -0.82% |
| Dec 31, 2022 | 133.80M | 4.45M | 3.44% |
| Dec 31, 2021 | 129.35M | 28.00M | 27.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BIONET | 1.26B |
| DIVA Laboratories | 884.63M |
| Genetics Generation Advancement | 609.13M |
| Kim Forest Enterprise | 549.14M |
| Sofiva Genomics | 382.82M |
| Welgene Biotech | 381.82M |
| Puriblood Medical | 82.34M |